GLYPHARMA THERAPEUTIC

GLyPharma was created in Montréal in August 2012 for the purpose of a strategic partnership between Ferring Pharmaceuticals, a European pharmaceutical company specialized in the discovery and development of active peptides, FONDS de solidarité FTQ and CTI Life Sciences Fund. The compound, FE 203799, is a long-acting GLP-2 receptor agonist, with intestine-trophic and intestine-protective activity. GLyPharma is granted by Ferring an exclusive worldwide license for development and commercialization of this compound as first-in-class indication in supportive care in oncology for protecting from chemotherapy-induced intestinal mucositis.

#People #Financial #Website #More

GLYPHARMA THERAPEUTIC

Industry:

Biotechnology Health Care Medical Therapeutics

Founded:

2012-08-01

Address:

Montréal, Quebec, Canada

Country:

Canada

Website Url:

http://www.glypharma.com

Total Employee:

1+

Status:

Active

Contact:

(514)876-4220

Email Addresses:

[email protected]

Total Funding:

12 M CAD

Technology used in webpage:

SPF Google Font API Amazon Amazon Virginia Region NameBright

Current Employees Featured

violetta-dimitriadou_image

Violetta Dimitriadou
Violetta Dimitriadou Senior Project Director @ GLyPharma Therapeutic
Senior Project Director
2013-02-01

micheline-beauvais_image

Micheline Beauvais
Micheline Beauvais Finance Director @ GLyPharma Therapeutic
Finance Director

jean-francois-leprince_image

Jean-Francois Leprince
Jean-Francois Leprince Interim CEO @ GLyPharma Therapeutic
Interim CEO

Investors List

cti-life-sciences-fund-2_image

CTI Life Sciences Fund

CTI Life Sciences Fund investment in Series A - GLyPharma Therapeutic

Official Site Inspections

http://www.glypharma.com

Host Informations
Whois Informations

Loading ...

More informations about "GLyPharma Therapeutic" on Search Engine